glp-1 ras list Market Overview: Agonists and the Obesity Market | Blog Classification of GLP-1 RAs based

doi: 10.1016/S0140-6736(17)30069-7 92 Pi-SunyerXAstrupAFujiokaKGreenwayFHalpernAKrempfMet al

Back in 2018, most of its earnings came from generics, with only a small share driven by innovation. Between 2025 and 2027, the company expects to bring dozens of major breakthroughs to market from GLP-1 therapies for obesity and diabetes to next-generation oncology treatments. Source: *Opinions are my own To view or add a comment, sign in Big Pharma News: Pfizer is set to acquire Metsera in a deal worth up to $4.9B Why it matters: $47.50/share upfront + $22.50/share tied to milestones Lead candidate MET-097i (GLP-1 therapy) showed 11.3% weight loss in 12 weeks Pipeline includes monthly amylin-based injections + oral obesity drugs Puts Pfizer head-to-head with Lilly & Novo Nordisk in the obesity race This move highlights the booming obesity drug market and pharmas growing appetite for metabolic innovation

This content is educational and provided by Dr

Whether you need to recover after a late night at Hustler Casino , rehydrate before heading to El Camino College , or boost your energy for a day at Rowley Park , weve got you covered

examined BPC-157s influence on musculoskeletal soft tissue repair and gastrointestinal cytoprotection across multiple animal models